avenanthramide A

Avenanthramide A (AVN A) is a naturally occurring phenolic alkaloid and phytoalexin derived from oat bran (*Avena sativa*). As a small molecule research compound, it has demonstrated significant antitumor activity, particularly in colorectal cancer (CRC), by targeting the oncogenic RNA helicase DDX3. AVN A binds to the Arg287 and Arg294 residues of DDX3, inhibiting its ATPase activity and promoting its degradation, which leads to mitochondrial dysfunction and apoptosis. Beyond oncology, AVN A exhibits potent anti-inflammatory, antioxidant, and anti-melanogenic properties. In dermatological research, it has been shown to inhibit tyrosinase and reduce proinflammatory cytokines, suggesting potential therapeutic utility in treating atopic dermatitis and post-inflammatory hyperpigmentation. Research is primarily led by academic institutions including Shanxi University and MD Anderson Cancer Center.

Other names

avenanthramide AAVN A2-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid